Gene-guided Warfarin for Anticoagulation Therapy
Not Applicable
Withdrawn
- Conditions
- Stroke
- Interventions
- Device: Gene detection (CYP2C9*3, VKORC1)
- Registration Number
- NCT04482842
- Brief Summary
This study will explore the effect of warfarin gene polymorphism on the effectiveness and safety of anticoagulant therapy in patients with acute ischemic stroke, and clarify the correlation between genetic testing and compliance rate of INR value. It will illustrate the significance of gene-guided warfarin for administered dose to anticoagulation therapy in patients with acute ischemic stroke. Then it will establish and verify a warfarin stable dose prediction model suitable for such patients, and provide basis for the personalized medication regimen of warfarin in patients with acute ischemic stroke.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Patients with acute ischemic stroke aged ≥18 years (cardiogenic cerebral embolism patients)
- Clinicians judge that long-term oral anticoagulation with warfarin is required
- No anticoagulation treatment in the past 10 days
- Agree to participate in this project
Exclusion Criteria
- Patients who had a tendency to bleed when taking warfarin
- High-risk groups using warfarin anticoagulation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Gene-guided Warfarin Gene detection (CYP2C9*3, VKORC1) - Gene-guided Warfarin Warfarin Sodium - Routine use Warfarin Sodium -
- Primary Outcome Measures
Name Time Method Stroke recurrence rate, compliance rate of INR value 12 months Evaluation and analysis of the stroke recurrence rate and compliance rate of INR value at 12 months after treatment
- Secondary Outcome Measures
Name Time Method